Do analysts prefer PRPO or XGN?

Exagen has a consensus target price of $9.63, suggesting a potential upside of 21.53%. Given Exagen's stronger consensus rating and higher possible upside, analysts clearly believe Exagen is more favorable than Precipio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Precipio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Exagen 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89

Which has better earnings & valuation, PRPO or XGN?

Precipio has higher earnings, but lower revenue than Exagen. Precipio is trading at a lower price-to-earnings ratio than Exagen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Precipio $24.05M 2.27 -$360K -$0.64 N/A Exagen $66.57M 2.88 -$19.95M -$0.81 N/A

Is PRPO or XGN more profitable?

Precipio has a net margin of -4.47% compared to Exagen's net margin of -26.61%. Precipio's return on equity of -8.49% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets Precipio -4.47% -8.49% -5.75% Exagen -26.61% -104.46% -28.93%

Does the media favor PRPO or XGN?

In the previous week, Precipio and Precipio both had 2 articles in the media. Exagen's average media sentiment score of 1.76 beat Precipio's score of 0.33 indicating that Exagen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precipio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Exagen 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts rate LFMD or PRPO?

LifeMD presently has a consensus price target of $7.57, indicating a potential upside of 128.74%. Given LifeMD's stronger consensus rating and higher possible upside, analysts plainly believe LifeMD is more favorable than Precipio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LifeMD 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70 Precipio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, LFMD or PRPO?

LifeMD has higher revenue and earnings than Precipio. LifeMD is trading at a lower price-to-earnings ratio than Precipio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LifeMD $194.05M 0.82 $14.35M -$0.05 N/A Precipio $24.05M 2.27 -$360K -$0.64 N/A

Is LFMD or PRPO more profitable?

LifeMD has a net margin of 0.10% compared to Precipio's net margin of -4.47%. Precipio's return on equity of -8.49% beat LifeMD's return on equity. Company Net Margins Return on Equity Return on Assets LifeMD 0.10% -168.23% -31.27% Precipio -4.47% -8.49% -5.75%

Does the media refer more to LFMD or PRPO?

In the previous week, LifeMD had 3 more articles in the media than Precipio. MarketBeat recorded 5 mentions for LifeMD and 2 mentions for Precipio. LifeMD's average media sentiment score of 0.69 beat Precipio's score of 0.33 indicating that LifeMD is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LifeMD 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Precipio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend JYNT or PRPO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Joint 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Precipio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, JYNT or PRPO?

Joint has higher revenue and earnings than Precipio. Precipio is trading at a lower price-to-earnings ratio than Joint, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Joint $58.55M 2.04 $2.91M $0.27 31.26 Precipio $24.05M 2.27 -$360K -$0.64 N/A

Is JYNT or PRPO more profitable?

Joint has a net margin of 6.49% compared to Precipio's net margin of -4.47%. Joint's return on equity of 12.02% beat Precipio's return on equity. Company Net Margins Return on Equity Return on Assets Joint 6.49% 12.02% 3.47% Precipio -4.47% -8.49% -5.75%

Do analysts rate PRPO or ACH?

Accendra Health has a consensus target price of $1.50, indicating a potential upside of 25.00%. Given Accendra Health's stronger consensus rating and higher probable upside, analysts clearly believe Accendra Health is more favorable than Precipio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Precipio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Accendra Health 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80

Does the media prefer PRPO or ACH?

In the previous week, Accendra Health had 2 more articles in the media than Precipio. MarketBeat recorded 4 mentions for Accendra Health and 2 mentions for Precipio. Accendra Health's average media sentiment score of 0.56 beat Precipio's score of 0.33 indicating that Accendra Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precipio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Accendra Health 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate PRPO or PARK?

Park Dental Partners has a consensus target price of $28.50, suggesting a potential upside of 38.28%. Given Park Dental Partners' stronger consensus rating and higher probable upside, analysts plainly believe Park Dental Partners is more favorable than Precipio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Precipio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Park Dental Partners 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has stronger earnings and valuation, PRPO or PARK?

Precipio is trading at a lower price-to-earnings ratio than Park Dental Partners, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Precipio $24.05M 2.27 -$360K -$0.64 N/A Park Dental Partners $251.37M 0.39 -$360K $1.05 19.63

Does the media refer more to PRPO or PARK?

In the previous week, Precipio and Precipio both had 2 articles in the media. Park Dental Partners' average media sentiment score of 1.84 beat Precipio's score of 0.33 indicating that Park Dental Partners is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precipio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Park Dental Partners 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Precipio (PRPO) Competitors

$30.45 +1.02 (+3.47%)

As of 08/21/2026 04:00 PM Eastern

Compare

PRPO vs. XGN, LFMD, JYNT, ACH, and PARK

Should you buy Precipio stock or one of its competitors? Precipio's main competitors and comparable companies include Exagen (XGN), LifeMD (LFMD), Joint (JYNT), Accendra Health (ACH), and Park Dental Partners (PARK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Precipio compare to Exagen?

Precipio (NASDAQ:PRPO) and Exagen (NASDAQ:XGN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Exagen has a consensus target price of $9.63, suggesting a potential upside of 21.53%. Given Exagen's stronger consensus rating and higher possible upside, analysts clearly believe Exagen is more favorable than Precipio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precipio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Exagen	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Precipio has a net margin of -4.47% compared to Exagen's net margin of -26.61%. Precipio's return on equity of -8.49% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precipio	-4.47%	-8.49%	-5.75%
Exagen	-26.61%	-104.46%	-28.93%

Precipio has higher earnings, but lower revenue than Exagen. Precipio is trading at a lower price-to-earnings ratio than Exagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precipio	$24.05M	2.27	-$360K	-$0.64	N/A
Exagen	$66.57M	2.88	-$19.95M	-$0.81	N/A

Precipio has a beta of 1.3, meaning that its stock price is 30% more volatile than the broader market. Comparatively, Exagen has a beta of 2.05, meaning that its stock price is 105% more volatile than the broader market.

In the previous week, Precipio and Precipio both had 2 articles in the media. Exagen's average media sentiment score of 1.76 beat Precipio's score of 0.33 indicating that Exagen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precipio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Exagen	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

10.5% of Precipio shares are held by institutional investors. Comparatively, 75.3% of Exagen shares are held by institutional investors. 16.6% of Precipio shares are held by insiders. Comparatively, 10.4% of Exagen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Exagen beats Precipio on 10 of the 16 factors compared between the two stocks.

How does Precipio compare to LifeMD?

LifeMD (NASDAQ:LFMD) and Precipio (NASDAQ:PRPO) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation.

LifeMD has a net margin of 0.10% compared to Precipio's net margin of -4.47%. Precipio's return on equity of -8.49% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LifeMD	0.10%	-168.23%	-31.27%
Precipio	-4.47%	-8.49%	-5.75%

In the previous week, LifeMD had 3 more articles in the media than Precipio. MarketBeat recorded 5 mentions for LifeMD and 2 mentions for Precipio. LifeMD's average media sentiment score of 0.69 beat Precipio's score of 0.33 indicating that LifeMD is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LifeMD	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Precipio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

LifeMD has a beta of 2.02, indicating that its share price is 102% more volatile than the broader market. Comparatively, Precipio has a beta of 1.3, indicating that its share price is 30% more volatile than the broader market.

LifeMD presently has a consensus price target of $7.57, indicating a potential upside of 128.74%. Given LifeMD's stronger consensus rating and higher possible upside, analysts plainly believe LifeMD is more favorable than Precipio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LifeMD	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Precipio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

LifeMD has higher revenue and earnings than Precipio. LifeMD is trading at a lower price-to-earnings ratio than Precipio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LifeMD	$194.05M	0.82	$14.35M	-$0.05	N/A
Precipio	$24.05M	2.27	-$360K	-$0.64	N/A

35.5% of LifeMD shares are owned by institutional investors. Comparatively, 10.5% of Precipio shares are owned by institutional investors. 17.2% of LifeMD shares are owned by company insiders. Comparatively, 16.6% of Precipio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

LifeMD beats Precipio on 12 of the 16 factors compared between the two stocks.

How does Precipio compare to Joint?

Joint (NASDAQ:JYNT) and Precipio (NASDAQ:PRPO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Joint	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Precipio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

76.9% of Joint shares are owned by institutional investors. Comparatively, 10.5% of Precipio shares are owned by institutional investors. 30.2% of Joint shares are owned by company insiders. Comparatively, 16.6% of Precipio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Joint has higher revenue and earnings than Precipio. Precipio is trading at a lower price-to-earnings ratio than Joint, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Joint	$58.55M	2.04	$2.91M	$0.27	31.26
Precipio	$24.05M	2.27	-$360K	-$0.64	N/A

Joint has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market. Comparatively, Precipio has a beta of 1.3, suggesting that its stock price is 30% more volatile than the broader market.

In the previous week, Precipio had 2 more articles in the media than Joint. MarketBeat recorded 2 mentions for Precipio and 0 mentions for Joint. Precipio's average media sentiment score of 0.33 beat Joint's score of -0.28 indicating that Precipio is being referred to more favorably in the news media.

Company	Overall Sentiment
Joint	Neutral
Precipio	Neutral

Joint has a net margin of 6.49% compared to Precipio's net margin of -4.47%. Joint's return on equity of 12.02% beat Precipio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Joint	6.49%	12.02%	3.47%
Precipio	-4.47%	-8.49%	-5.75%

Summary

Joint beats Precipio on 10 of the 14 factors compared between the two stocks.

How does Precipio compare to Accendra Health?

Precipio (NASDAQ:PRPO) and Accendra Health (NYSE:ACH) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings and media sentiment.

Precipio has a beta of 1.3, suggesting that its stock price is 30% more volatile than the broader market. Comparatively, Accendra Health has a beta of 1.58, suggesting that its stock price is 58% more volatile than the broader market.

Precipio has higher earnings, but lower revenue than Accendra Health. Precipio is trading at a lower price-to-earnings ratio than Accendra Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precipio	$24.05M	2.27	-$360K	-$0.64	N/A
Accendra Health	$2.73B	0.03	-$1.10B	-$3.91	N/A

Precipio has a net margin of -4.47% compared to Accendra Health's net margin of -11.41%. Accendra Health's return on equity of -4.02% beat Precipio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precipio	-4.47%	-8.49%	-5.75%
Accendra Health	-11.41%	-4.02%	0.70%

10.5% of Precipio shares are owned by institutional investors. 16.6% of Precipio shares are owned by company insiders. Comparatively, 2.3% of Accendra Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Accendra Health has a consensus target price of $1.50, indicating a potential upside of 25.00%. Given Accendra Health's stronger consensus rating and higher probable upside, analysts clearly believe Accendra Health is more favorable than Precipio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precipio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Accendra Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

In the previous week, Accendra Health had 2 more articles in the media than Precipio. MarketBeat recorded 4 mentions for Accendra Health and 2 mentions for Precipio. Accendra Health's average media sentiment score of 0.56 beat Precipio's score of 0.33 indicating that Accendra Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precipio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Accendra Health	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Accendra Health beats Precipio on 9 of the 15 factors compared between the two stocks.

How does Precipio compare to Park Dental Partners?

Precipio (NASDAQ:PRPO) and Park Dental Partners (NASDAQ:PARK) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment.

Park Dental Partners has a net margin of 0.00% compared to Precipio's net margin of -4.47%. Park Dental Partners' return on equity of 0.00% beat Precipio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precipio	-4.47%	-8.49%	-5.75%
Park Dental Partners	N/A	N/A	N/A

10.5% of Precipio shares are held by institutional investors. 16.6% of Precipio shares are held by insiders. Comparatively, 10.6% of Park Dental Partners shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Precipio and Precipio both had 2 articles in the media. Park Dental Partners' average media sentiment score of 1.84 beat Precipio's score of 0.33 indicating that Park Dental Partners is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precipio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Park Dental Partners	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Precipio is trading at a lower price-to-earnings ratio than Park Dental Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precipio	$24.05M	2.27	-$360K	-$0.64	N/A
Park Dental Partners	$251.37M	0.39	-$360K	$1.05	19.63

Park Dental Partners has a consensus target price of $28.50, suggesting a potential upside of 38.28%. Given Park Dental Partners' stronger consensus rating and higher probable upside, analysts plainly believe Park Dental Partners is more favorable than Precipio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precipio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Park Dental Partners	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Park Dental Partners beats Precipio on 11 of the 14 factors compared between the two stocks.

Get Precipio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRPO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRPO vs. The Competition

Export

Metric	Precipio	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$54.51M	$9.83B	$7.37B	$12.85B
Dividend Yield	N/A	2.55%	2.53%	11.08%
P/E Ratio	-47.58	34.38	272.60	24.24
Price / Sales	2.27	4.97	618.96	99.81
Price / Cash	38.33	125.12	78.62	53.99
Price / Book	3.70	4.05	13.05	6.20
Net Income	-$360K	$311.06M	$3.47B	$348.59M
7 Day Performance	29.57%	0.83%	2.09%	0.08%
1 Month Performance	33.09%	2.42%	6.64%	3.88%
1 Year Performance	113.53%	15.69%	25.02%	16.98%

Precipio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRPO Precipio	0.4299 of 5 stars	$30.45 +3.5%	N/A	+113.5%	$54.51M	$24.05M	N/A	60	News Coverage Earnings Report
XGN Exagen	3.8449 of 5 stars	$7.03 +6.7%	$9.63 +36.9%	-21.6%	$170.10M	$66.57M	N/A	220	Positive News
LFMD LifeMD	2.78 of 5 stars	$3.38 +3.2%	$7.57 +124.3%	-47.7%	$162.68M	$194.05M	N/A	230
JYNT Joint	1.8693 of 5 stars	$8.22 -3.8%	N/A	-20.5%	$116.16M	$54.90M	30.43	320
ACH Accendra Health	2.2561 of 5 stars	$1.31 +15.5%	$1.50 +14.9%	N/A	$100.37M	$2.73B	N/A	6,500	Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRPO) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Precipio (PRPO) Competitors